Vanguard Group Inc. Has $3 Billion Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Vanguard Group Inc. increased its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 0.8% in the fourth quarter, Holdings Channel.com reports. The firm owned 12,733,399 shares of the biopharmaceutical company’s stock after buying an additional 98,303 shares during the quarter. Vanguard Group Inc. owned about 0.10% of Alnylam Pharmaceuticals worth $2,996,296,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in ALNY. Regeneron Pharmaceuticals Inc. acquired a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter valued at about $1,045,822,000. Geode Capital Management LLC raised its holdings in Alnylam Pharmaceuticals by 3.2% in the 3rd quarter. Geode Capital Management LLC now owns 2,147,203 shares of the biopharmaceutical company’s stock valued at $589,209,000 after buying an additional 66,928 shares during the last quarter. American Century Companies Inc. boosted its position in Alnylam Pharmaceuticals by 0.7% during the 4th quarter. American Century Companies Inc. now owns 1,604,024 shares of the biopharmaceutical company’s stock worth $377,443,000 after buying an additional 11,291 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in Alnylam Pharmaceuticals by 5.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 513,962 shares of the biopharmaceutical company’s stock worth $120,940,000 after acquiring an additional 26,614 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. increased its position in Alnylam Pharmaceuticals by 3.0% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 286,703 shares of the biopharmaceutical company’s stock valued at $67,464,000 after acquiring an additional 8,462 shares during the period. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

ALNY stock opened at $280.96 on Wednesday. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. The business has a 50-day simple moving average of $258.62 and a two-hundred day simple moving average of $260.26. The company has a market capitalization of $36.37 billion, a P/E ratio of -129.47 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a 52-week low of $141.98 and a 52-week high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.03). Research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Analyst Ratings Changes

ALNY has been the topic of several analyst reports. JPMorgan Chase & Co. raised shares of Alnylam Pharmaceuticals from a “neutral” rating to an “overweight” rating and boosted their price objective for the stock from $280.00 to $328.00 in a research note on Monday. Wells Fargo & Company upped their price target on Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the company an “equal weight” rating in a research report on Friday, March 21st. Scotiabank lifted their price objective on Alnylam Pharmaceuticals from $300.00 to $338.00 and gave the stock a “sector outperform” rating in a research note on Friday, March 21st. William Blair reissued an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Friday, March 21st. Finally, Morgan Stanley boosted their price target on shares of Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the stock an “equal weight” rating in a research report on Friday, February 14th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty have given a buy rating to the stock. According to MarketBeat.com, Alnylam Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $312.30.

Insider Activity at Alnylam Pharmaceuticals

In related news, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $251.56, for a total transaction of $362,246.40. Following the completion of the sale, the executive vice president now directly owns 12,881 shares of the company’s stock, valued at approximately $3,240,344.36. This trade represents a 10.06 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CMO Pushkal Garg sold 52,592 shares of the company’s stock in a transaction on Monday, January 27th. The shares were sold at an average price of $285.00, for a total value of $14,988,720.00. Following the completion of the transaction, the chief marketing officer now owns 11,989 shares of the company’s stock, valued at $3,416,865. This trade represents a 81.44 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 71,234 shares of company stock valued at $19,958,097 over the last ninety days. Corporate insiders own 1.50% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.